ICAM1 and cancer: Another dual FAK/Pyk2 pharmacological inhibitor (VS-6063) currently in development as a cancer therapy44 also efficiently reduced VCAM-1, ICAM-1, and E-selectin expression in a dose dependent manner in HAoECs (Supp.